• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.15
  • VXN 19.51
  • VXO 16.03
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
()
Last Trade Dividend/Share PE Ratio
Date Dividend Yield Return on Assets
Change ExDividend Date Return on Capital
Bid Latest EPS Price/Sale
Ask LatestEPS Date Price to Book
Volume EPS ttm Institutional %
Avg Volume Shares Outstanding Insider %
Open Float Short Ratio
Prev Close Return On Equity 5 Year Change %
High Consensus EPS 2 Year Change %
Low No. of Estimate 1 Year Change %
52 Week High EPS Surprise $ YTD Change %
52 Week Low EPS Surprise Percent 6 Month Change %
52 Week Change EBITDA 3 Month Change %
50 Day MA Revenue 1 Month Change %
200 Day MA Gross Profit 5 Day Change %
Market Cap Cash 30 Day Change %
Beta Debt Stock Exchange
Sector Revenue Per Share Short Interest
Short Date Revenue Per Employee Short Ratio
Data courtesy of IEX
Company Profile

Amarin Corporation plc operates as a biopharmaceutical company with a focus on cardiovascular diseases. Its cardiovascular programs focus in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. The company?s lead product candidate includes AMR101, a prescription grade Omega-3 product comprising ultra-pure ethyl eicosapentaenoic acid, which is entering Phase III clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Its pipeline also includes programs in the area of central nervous system disorders, including Huntington?s disease, myasthenia gravis, and Parkinson?s disease. Amarin Corporation plc, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.